Patrick Harrison Carroll Sells 23,726 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares of the company’s stock, valued at $6,365,135. This trade represents a 11.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded down $0.54 on Tuesday, reaching $33.00. The company’s stock had a trading volume of 12,512,469 shares, compared to its average volume of 30,262,973. The company has a 50-day simple moving average of $27.02 and a 200 day simple moving average of $26.54. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company has a market cap of $7.64 billion, a P/E ratio of -366.67, a PEG ratio of 50.70 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.20 earnings per share. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Bank of America dropped their target price on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. Leerink Partners raised their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Citigroup lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Finally, UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $29.37.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its position in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares during the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. Norges Bank purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at $62,153,000. Invesco Ltd. boosted its stake in shares of Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the period. Finally, Clear Street Group Inc. bought a new position in shares of Hims & Hers Health in the third quarter worth about $87,372,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.